secwatch.observer — SEC 8-K summary
======================================

Issuer:     Adaptive Biotechnologies Corp (ADPT)
CIK:        0001478320
Form:       8-K
Filed at:   2025-08-05T23:59:59+00:00
Accession:  0000950170-25-103058
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Adaptive Q2 MRD revenue up 42%, achieves MRD profitability; raises FY guidance
------------------------------------------------------------------------------

- Total revenue $58.9M (+36% YoY); MRD revenue $49.9M (+42% YoY); MRD Adjusted EBITDA positive $1.9M.
- clonoSEQ volume 25,321 (+37% YoY); Immune Medicine revenue $8.9M (+13% YoY).
- Net loss $25.6M ($46.2M in Q2 2024); Adjusted EBITDA loss $7.2M vs $21.4M prior year.
- FY 2025 MRD revenue guidance raised to $190-200M (from $180-190M); cash burn guidance lowered to $45-55M.
- Cash $222M; launched clonoSEQ integration into Flatiron OncoEMR; recognized $5.5M pharma milestone revenue.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1478320/000095017025103058/0000950170-25-103058-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1478320/000095017025103058/adpt-20250805.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-103058

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer